Abbott Laboratories (ABT)

Net profit margin

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Net income (ttm)	US$ in thousands	13,402,000	5,767,000	5,557,000	5,630,000	5,723,000	5,162,000	5,161,000	5,804,000	6,933,000	7,889,000	8,554,000	7,725,000	7,071,000	7,244,000	6,376,000	5,724,000	4,495,000	3,382,000	3,110,000	3,579,000
Revenue (ttm)	US$ in thousands	41,950,000	41,217,000	40,725,000	40,326,000	40,109,000	39,959,000	40,226,000	41,505,000	43,653,000	45,030,000	45,548,000	44,514,000	43,075,000	42,308,000	40,233,000	37,338,000	34,608,000	32,221,000	31,444,000	32,095,000
Net profit margin		31.95%	13.99%	13.65%	13.96%	14.27%	12.92%	12.83%	13.98%	15.88%	17.52%	18.78%	17.35%	16.42%	17.12%	15.85%	15.33%	12.99%	10.50%	9.89%	11.15%

December 31, 2024 calculation

Net profit margin = Net income (ttm) ÷ Revenue (ttm)
= $13,402,000K ÷ $41,950,000K
= 31.95%

Abbott Laboratories has shown fluctuations in its net profit margin over the reported periods, ranging from a low of 9.89% in June 2020 to a high of 31.95% in December 2024. Despite the variability, the company has generally maintained healthy profitability levels, with margins consistently above 10%. Notably, there was a significant spike in the net profit margin at the end of December 2024, reaching an unusually high level of 31.95%. This exceptional performance may be attributed to various factors such as strong revenue growth, cost management initiatives, or one-time gains. However, it is essential to assess the sustainability of such exceptional profitability levels and closely monitor future financial performance to gauge the company's long-term profitability prospects.